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Abstract
Background: The surgeon's contribution to patients with localized pancreatic adenocarcinoma (PAC) is
a margin negative (R0) resection. We hypothesized that a prediction rule based on pre-operative imaging
would maximize the R0 resection rate while reducing non-therapeutic intervention.
Methods: The prediction rule was developed using computed tomography (CT) and endoscopic ultra-
sound (EUS) data from 65 patients with biopsy-proven PAC who underwent attempted resection. The rule
classified patients as low or high risk for non-R0 outcome and was validated in 78 subsequent patients.
Results: Model variables were: any evidence of vascular involvement on CT; EUS stage and EUS size
dichotomized at 2.6 cm. In the validation cohort, 77% underwent resection and 58% achieved R0 status.
If only patients in the low-risk group underwent surgery, the prediction rule would have increased the
resection rate to 92% and the R0 rate to 73%. The R0 rate was 40% higher in low-risk compared with
high-risk patients (P < 0.001). High risk was associated with a 67% rate of non-curative surgery
(unresectable disease and metastases).
Conclusion: The prediction rule identified patients most likely to benefit from resection for PAC using
pre-operative CT and EUS findings. Model predictions would have increased the R0 rate and reduced
non-therapeutic interventions.
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Introduction
Margin-negative (R0) surgical resection is the only treatment for
pancreatic adenocarcinoma demonstrating actual 5-year sur-
vival.1 As a result, the criteria for identifying patients with local-
ized pancreatic cancer for resection are currently the most critical
aspect of treatment for early stage disease. Published indicators of
resectability and borderline resectability have achieved the status
of an expert consensus definition despite the absence of a rigorous
prospective validation of their accuracy at predicting R0 outcome
or the potential survival benefit of surgical intervention.2 Con-
versely, the post-operative morbidity and negative survival impact
of non-therapeutic surgical interventions such as ‘open and close’
procedures for unexpected metastases as well as bypass proce-
dures for unresectable disease have not been evaluated in a pro-
spective clinical trial of surgical treatment using intention-to-treat
methodology. This knowledge deficit has reduced formal risk-
benefit analysis of surgical treatment for patients with localized
pancreatic adenocarcinoma to a simplistic ‘surgery/no surgery’
decision.
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The current definition of ‘resectable’ pancreatic cancer requires:
the absence of extrapancreatic disease; no evidence of tumour
extension to the superior mesenteric artery or celiac axis as
defined by an intact fat plane between the tumour and the adja-
cent visceral artery; a patent superior mesenteric-portal vein con-
fluence; and no encasement of the portal or superior mesenteric
vein. These criteria are a strictly ‘operational’ definition of resec-
tability based on anatomic factors favouring a technically safe
surgical procedure. They are routinely applied by surgeons select-
ing patients likely to benefit from successful attempted resection,
but there is limited data stratifying the risks of surgical explora-
tion particularly for non-R0 outcomes such as margin-positivity
or metastatic disease. Furthermore, individualized treatment
planning for pancreatic cancer patients requires a consideration
of additional survival factors including the risk of early cancer
progression, tumour biology, post-operative morbidity and mor-
tality, and the relative merits of alternative strategies such as
neoadjuvant-combined modality therapy.
We therefore tested the hypothesis that a prediction rule could
be developed and validated to maximize the rate of R0 resection
among patients with localized pancreatic cancer using a combi-
nation of imaging characteristics identified on pre-operative
computed tomography (CT) and endoscopic ultrasound (EUS)
studies. Multidetector, contrast-enhanced CT and EUS are com-
plimentary modalities routinely used to determine respectabil-
ity,3,4 and imaging predictors of unresectable disease have been
reasonably well established.5,6 However, combining the two to
develop and validate a prediction rule for resectability has not
been performed. Establishing evidence-based criteria for surgical
intervention in early stage pancreatic cancer may standardize
treatment decisions across institutions, reduce the risk of non-
therapeutic operations and permit a definition of resectable pan-
creatic cancer based on empirical outcomes rather than technical
safety.
Methods
All study procedures were approved by the Institutional Review
Board of the University of Pittsburgh.We analysed a de-identified
dataset of patients with pathologically-confirmed pancreatic
adenocarcinoma who underwent surgery at the University of
PittsburghMedical Center (UPMC) between 2002–2007. The data
included: age and gender, serum biochemistry, clinical reports of
pre-operative CT scans and EUS, operative reports, surgical
pathology, post-operative outcomes, the provision of adjuvant
chemotherapy and/or chemoradiation, as well as oncologic
follow-up. CT and EUS findings were abstracted directly from the
clinical reports that were available to the surgeon pre-operatively
and used to formulate the original treatment plan for potentially-
resectable pancreatic cancer. Post-hoc analysis of these images was
not performed.
The generation and testing of the prediction rule utilized inde-
pendent training and validation cohorts of patients that under-
went both helical pancreas mass protocol CT and EUS performed
by a dedicated pancreatic endosonographer during their initial
evaluation for pancreatic cancer. Patients referred for neoadjuvant
therapy for any reason were excluded. The training cohort con-
sisted of 65 patients who underwent surgical exploration for pan-
creatic adenocarcinoma between 2002–2005 at UPMC. Recursive
partitioning of CT, EUS and pathologic data was then used to
create a prediction rule (classification tree) classifying patients
into two risk categories for R0 resectability (high/low). The ‘tree’
function in Splus 2000 (MathSoft Inc., Seattle,WA,USA) was used
to develop a series of candidate prediction rules, and the final
prediction rule was selected using cross-validation to compare the
misclassification rates of candidate rules. In cross-validation, 90%
of the data are used for training and 10% are used to compute the
misclassification rate; the procedure is repeated with all possible
non-overlapping 10% samples of the data.
The classification tree with the smallest misclassification rate
utilized EUS and CT variables (Fig. 1). These variables are (i) a
binary variable indicating any evidence of arterial or venous vas-
cular involvement on CT; (ii) the combination of EUS T and N
data to assign a pre-operative stage according to the criteria of the
American Joint Committee on Cancer (AJCC) 6th edn,7 and (iii)
a binary variable indicating whether the largest EUS tumour
dimension was greater than 2.6 cm. The prediction rule is the
following: a patient is considered a good candidate for R0 resec-
tion (low risk) and should undergo surgery as primary therapy if
(i) the EUS stage is1A, or (ii) if there is no vascular involvement
on CT and EUS stage is either 1B or 2A, or (iii) if there is no
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Figure 1 Classification tree and surgical outcomes after application
of the prediction rule. R0 margin-negative resection; R1 margin-
positive; LA locally advanced unresectable disease; met metastases
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vascular involvement on CT and EUS stage is 2B and higher but
the largest tumour dimension is2.6 cm; otherwise, a patient is a
poor candidate for R0 resection (high risk). Evidence for vascular
involvement by CT scan includes minimal abutment of the supe-
rior mesenteric or hepatic arteries without extension to the celiac
axis, as well as any pre-operative suspicion that the tumour
involves the superior mesenteric-portal vein confluence despite
the possibility of venous resection and reconstruction. Patients
with more extensive arterial encasement or venous occlusion were
referred for neoadjuvant protocols and were not included in this
study. For the purposes of this prediction rule, operative findings
of metastatic or locally advanced disease as well as positive resec-
tion margins were considered treatment failures.
The resulting prediction rule was next applied to a validation
cohort of 78 patients who underwent surgical exploration for
what was considered resectable pancreatic adenocarcinoma
between 2005–2007, all of whom were staged with CT and EUS.
The assessment of resectability was made by individual surgeons
at this high-volume tertiary referral centre for pancreatic cancer.
Patients with suspected metastases and those who had received
neoadjuvant therapy for any reason were again excluded. The
cohort was retrospectively classified into high-risk and low-risk
groups for curative resection using the model, and outcomes were
analysed based on that classification. All patients that underwent
surgery for potentially-resectable pancreatic cancer were included
in the analysis regardless of treatment outcome. No patients were
withdrawn from analysis, and the outcome assessments were
obtained in a like and unbiased manner for all patients. The high-
and low-risk groups were compared in terms of R0 and overall
resectability, the incidence of metastatic or locally-advanced
disease at operation and margin positivity. Final clinical and
pathologic staging were also compared, with staging based upon
pathology for resected specimens. For unresected patients, in
keeping with the spirit of the AJCC staging system, patients were
declared Stage 3 if they had an unresectable primary tumour even
in the absence of pathologic confirmation that the celiac axis or
superior mesenteric artery was involved. Unreconstructable
venous involvement by tumour was also categorized Stage 3. Liver
or peritoneal metastases and nodal involvement outside the limits
of normal resection (e.g. a positive para-aortic node) were con-
sidered Stage 4.
Statistical analysis
The prediction rule sensitivity, specificity and predictive values for
R0 resection were calculated using standard methods. Categorical
data were analysed using contingency table methods, applying
Fisher’s exact test.Wilcoxon’s rank-sum test was used to compare
the stage and nodal distributions between groups. For curative
surgery, ratios between the two groups with 95% confidence inter-
vals were also calculated. In addition, survival curves from date of
surgery were estimated using the Kaplan–Meier method and the
distributions compared with the log-rank test. Two-sided tests
were used and results considered statistically significant at the
P < 0.05 level. Data analyses were carried out with Stata 10.1
(StataCorp LP, College Station, TX,USA), SAS 9.1.3 (SAS Institute
Inc, Cary, NC, USA) and StatXact 4.0.1 (Cytel Software Corp,
Cambridge, MA, USA).
Results
The demographic profile of the validation cohort was typical for
pancreatic cancer; the average age at surgery was 68  11 years
(mean  SD) with 40 (51%) men and 38 (49%) women. The
majority of tumours were located in the pancreatic head (60/78,
77%) compared with the pancreatic body/tail (18/78, 23%). The
median tumour diameter based on pre-operative imaging was
2.6 cm (0.8 to 6.1 cm) among head lesions and 2.7 cm (0.7 to
5.9 cm) in the body/tail.
The observed resection rate among study subjects was 77%
(60/78) (Table 1). Of resected patients, 45 (75%) underwent
pancreaticoduodenectomy with 5 (11%) requiring portal vein
resection and reconstruction (PVR). Fifteen patients (25%)
received distal pancreatectomy. Thirteen patients had unexpected
metastases at the time of exploration and did not undergo resec-
tion, and five had unresectable locally-advanced disease. On final
pathology, the median diameter of lesions in the pancreatic head
was 3 cm (range 1–7.5) compared with 3.5 cm (range 1–8.2) in
the pancreatic body/tail. The majority of resected tumours
(58%, 35/60) were node positive. Forty-five patients had negative
Table 1 Demographic characteristics and pathologic outcomes of
78 patients explored for ‘resectable’ pancreatic cancer. Outcomes
were analyzed on an intention-to-treat basis as all patients under-
went surgery with curative intent
Characteristic Number of
patients
(%) n = 78
Tumour location Head 60 (77)
Body/Tail 18 (23)
Surgical outcome Resected 60 (76)
R0 45 (58)
R1 15 (19)
Not Resected 18 (23)
Locally advanced 5 (6)
Metastatic 13 (17)
AJCC stage, 6th edn. 1A 3 (4)
1B 5 (6)
2A 17 (22)
2B 35 (45)
3 5 (6)
4 13 (17)
Adjuvant chemotherapy 48 (76)a
Adjuvant radiation 16 (27)b
aData for adjuvant chemotherapy were available for 63 patients.
bData for adjuvant radiation were available for 60 patients.
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surgical margins and 15 patients had microscopically positive
margins (R1), 4 of whom had two sites of microscopic residual
disease on final pathology. Two out of five (40%) patients requir-
ing PVR had an R0 result. No patients had grossly positive
margins (R2 resection). The margin most frequently involved by
tumour was the retroperitoneal/SMA margin (8/19 positive
margins, 42%), followed by the radial pancreatic margin adjacent
to the portal vein (6/19, 32%) and the pancreatic transection
margin (5/19, 26%).
The majority of patients with available data received adjuvant
chemotherapy (48/63, 76%) whereas fewer received adjuvant
radiation (16/60, 27%). There was no significant association
between the location of the tumour and the surgical outcome
(Table 2). The overall resectability rates for cancers in the proxi-
mal and distal pancreas were similar (75% vs. 83%, respectively),
as were the R0 (57% vs. 61%) and R1 (18% vs. 22%) resection
rates. At the time of survival analysis, 44 (56%) patients had died
with median follow-up among survivors of 17.1 months (range
1.5–31.9 months).
Figure 1 shows the surgical outcomes of patients grouped by
predicted risk. Summary data are shown in Table 3. The observed
rate of R0 resection for the entire 78 patient cohort was 58%.
Overall, the prediction rule demonstrated 71% accuracy, 78%
sensitivity and 61% specificity for R0 resection. The low-risk
group had a significantly greater chance of R0 resection compared
with the high-risk group (73% vs. 33% R0, P = 0.0009). Further-
more, the overall resection rate (R0 + R1) among low-risk patients
was 92% compared with 53% in the high-risk group (P < 0.0002).
Additional operative findings distinguishing the two risk groups
included a greater proportion of unresectable, locally-advanced
tumours (17% vs. 0%, P = 0.007) as well as unexpected metastatic
disease (30% vs. 8%, P = 0.026) in the high-risk group. Of the five
portal vein resections performed, two were in the low and three in
the high-risk groups, respectively. The rate of margin positivity in
resected patients was greater in the high-risk group but did not
achieve statistical significance (38% vs. 20%, P = 0.195).
High predicted risk of surgical failure corresponded to more
advanced stages of disease on final surgical pathology (Table 3).
The high-risk group demonstrated a significant distribution
towards higher AJCC stage, with 14/30 patients having stage 3
compared with 4/48 in the low-risk group (P < 0.0001). This
finding reflects the greater proportion of locally-advanced and
metastatic tumours in the high-risk group. However, the risk pre-
diction did not differentiate between patients at high and low risk
of nodal involvement (62% vs. 57%, P = 0.69). There were no
significant differences between the low and high-risk groups in the
median number of nodes harvested (low: 10, range 3–34; high: 12,
range 4–41), median numbers of positive lymph nodes (low: 2,
range 1–10; high: 3, range 1–10) or lymph node ratios among
resected patients with node positive disease (low: mean 0.33 
0.23 SD; high: 0.27  0.24 SD).
The risk classification also correlated with post-operative
overall survival. Median survival for the entire validation cohort
was 17.9 months (95% CI 12.8 to 22.5), with estimated 1- and
2-year survivals of 66% (95% CI 55% to 77%) and 36% (95% CI
22% to 50%), respectively. Median survival of the low-risk group
was 20.3 months compared with 12.1 months in the high-risk
group (P = 0.02). Regarding prognostic factors, tumour location
was similar between risk groups with 79% (38/48) of patients in
the low-risk group having tumours in the pancreatic head com-
pared with 73% (22/30) of patients in the high-risk group (P =
0.59). Likewise, rates of adjuvant chemotherapy were similar
between high- and low-risk prediction groups (73% vs. 78%,
P = 0.76).
Discussion
This study validates a prediction rule identifying a subset of
patients with potentially resectable pancreatic cancer that are at
high risk of non-curative surgical outcomes. Unlike consensus
definitions of resectability, this decision rule quantifies the likeli-
hood of treatment failure in individual patients based on readily
obtainable clinical parameters including EUS tumour diameter,
presence of local invasion and nodal involvement by EUS, as well
as signs of vascular abutment on CT. Patients at high predicted
risk had significantly greater rates of unresectable locally-
advanced as well as metastatic disease at the time of surgical
exploration with correspondingly lower rates of overall resectabil-
ity and R0 resection. Furthermore, unfavourable risk classification
was associated with more advanced AJCC stages on final pathol-
ogy and shorter overall survival. The classification tree formalizes
Table 2 Surgical treatment and outcomes stratified by tumour
location
Surgical outcome Tumour location, No. (%) P
Head (n = 60) Body/Tail (n = 18)
Resectability rate 45 (75) 15 (83) 0.54
R0 34 (56) 11 (61) 0.38
R1 11 (18) 4 (22)
Locally advanced 3 (5) 2 (11)
Metastatic disease 12 (20) 1 (5)
AJCC stage 1A 2 (3) 1 (5) 0.04
1B 1 (2) 4 (22)
2A 13 (22) 4 (22)
2B 29 (48) 6 (33)
3 3 (5) 2 (11)
4 12 (20) 1 (6)
Adjuvant chemotherapya 38 (76) 10 (77) 1.00
Adjuvant radiationb 12 (26) 4 (31) 0.73
Median survival, months 18.2 15.3 0.89
aData for adjuvant chemotherapy were known for 50 head and 13 body/
tail lesions.
bData for adjuvant radiation were known for 47 head and 13 body/tail
lesions.
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the selection of patients most likely to benefit from pancreatic
resection for adenocarcinoma. Ultimately, the model also presents
a new definition of borderline resectable pancreatic cancer based
on the statistical risk of treatment failure rather than the anatomic
relationships between a tumour and the adjacent vasculature.2
We used recursive partitioning to formulate the prediction rule.
This regression technique is a practical alternative to traditional
methods such as logistic regression analysis. Although nomo-
grams can distil a logistic regression model into a user-friendly
decision-support tool, recursive partitioning creates a classifica-
tion tree which mimics clinical decision making and simplifies
risk stratification. The current risk model is composed solely of
imaging parameters that are available to the surgeon at the time of
preoperative decision making. The model is therefore more clini-
cally applicable than published prognostic nomograms for pan-
creatic cancer that rely on data available only after surgery has
been performed.8
Other groups have created scoring systems and used multivari-
able techniques to predict resectability of localized pancreatic
cancer.6,9 However, the resulting predictive models in the surgical
literature are rarely validated.Without prospective validation, pre-
dictive models are not expected to perform as well when applied
to data independent of the training set from which they were
derived. By comparison, our analysis was validated in a popula-
tion of patients completely independent of the ‘training’ set of
patients. The validation cohort represented the 2005–2007 time
period in our registry when improvements in imaging, staging
and selection of operative candidates might reduce the apparent
effectiveness of a prediction model derived from the older data
between 2002–2005.Moreover, we did not perform a retrospective
expert review of EUS or CT imaging that might inadvertently bias
application of the model or provide specialized information
unavailable to the surgeon at the time of the decision to attempt
resection. Consequently, data for the analysis were abstracted
directly from the original EUS and CT reports to reproduce the
staging information available pre-operatively and without knowl-
edge of the surgical outcomes.
Because the recursive model relies heavily upon accurate EUS
staging, the experience of endosonographers may limit the
broader applicability of this study’s findings to other practices.
However, our data showed EUS to have 80% sensitivity and 93%
specificity for vascular invasion; with 71% positive predictive
value for nodal involvement. These findings are comparable to
data published in the gastroenterology literature.6,10
The logical question is whether patients with apparently resec-
table tumours but features that when critically examined indicate
a high risk of non-R0 outcome should be considered a novel
indication for neoadjuvant therapy. Using intention-to-treat
analysis, the published R0 resection rate after neoadjuvant therapy
for resectable pancreatic cancer ranges from 50% to 66% at expe-
rienced centres as a result of disease progression, intolerance to
therapy and loss to follow up.11–13 This rate is not different from
the overall R0 rate after primary surgical therapy observed in the
current study but is significantly higher than the 33% R0 rate
Table 3 Surgical and pathologic outcomes stratified by risk classification
Outcome measure Predicted risk group
No. (%)
P
Low-risk (n = 48) High-risk (n = 30)
Resectability Rate 44 (92) 16 (53) <0.001
R0 35 (73) 10 (33) 0.001
R1 9 (19) 6 (20) 0.892
Locally-advanced 0 (0) 5 (17) 0.007
Metastatic 4 (8) 9 (30) 0.026
AJCC Stage 1A 3 (6) 0 (0) 0.002
1B 3 (6) 2 (6)
2A 13 (27) 4 (13)
2B 25 (52) 10 (33)
3 0 (0) 5 (17)
4 4 (8) 9 (30)
Median number of total nodes per specimen if resected (range) 10 (3–34) 12 (4–41) 0.30
Median number of positive nodes if Stage 2B (range) 2 (1–10) 3 (1–10) 0.81
Mean node ratio if Stage 2B (SD) 0.33 (0.23) 0.27 (0.24) 0.50
Adjuvant chemotherapya 32 (78) 16 (73) 0.76
Adjuvant radiationb 9 (23) 7 (33) 0.54
Tumour location, head 38 (79) 22 (73) 0.55
aData for adjuvant chemotherapy were known for 41 low-risk and 22 high-risk lesions.
bData for adjuvant radiation were known for 39 low-risk and 21 high-risk lesions.
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observed among patients at high predicted risk. Conceptually,
neoadjuvant therapy may improve the outcome of surgery for
patients at risk for treatment failure by sterilizing the eventual
surgical margin and treating unrecognized systemic disease earlier
in the patient’s care.14 The high-risk group is an ideal population
for a randomized trial of neoadjuvant therapy given the statisti-
cally evident risk of treatment failure with surgery and conven-
tional adjuvant chemotherapy.15 Reduced median survival in the
high-risk group provides solid ethical justification for conducting
neoadjuvant clinical trials in a group of patients currently receiv-
ing surgical intervention. By stratifying risk, the prediction rule
proposed by this study may establish better endpoints in the
design and evaluation of such trials.
In conclusion, this validated prediction rule establishes a new
evidence-based definition of ‘resectable’ pancreatic cancer based
on surgical outcomes and overall survival. The model utilizes
readily available clinical parameters derived from EUS and CT and
demonstrated 71% accuracy, 78% sensitivity and 61% specificity
for R0 resection. In order to improve the quality of surgical man-
agement for pancreatic cancer we must better understand the
efficacy of therapies and diagnostic studies intended to increase
resectability as one contributor towards increasing long-term sur-
vival. The implications of a validated model to predict R0 resec-
tion on future clinical investigations, particularly alternative
treatment strategies such as the neoadjuvant approach for patients
at high risk of early progression, justifies a multicentre trial to
validate these conclusions.
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